Molecular Diagnosis & Therapy最新文献

筛选
英文 中文
Circulating C-Terminal Agrin Fragment is Associated with Impaired Physical Performance in Aging and Chronic Disease: A Systematic Review and Meta-Analysis. 循环c端Agrin片段与衰老和慢性病患者身体机能受损相关:一项系统综述和荟萃分析
IF 5.8 3区 医学
Molecular Diagnosis & Therapy Pub Date : 2026-11-15 DOI: 10.1007/s40291-026-00886-x
Rizwan Qaisar, Firdos Ahmad, Asima Karim
{"title":"Circulating C-Terminal Agrin Fragment is Associated with Impaired Physical Performance in Aging and Chronic Disease: A Systematic Review and Meta-Analysis.","authors":"Rizwan Qaisar, Firdos Ahmad, Asima Karim","doi":"10.1007/s40291-026-00886-x","DOIUrl":"https://doi.org/10.1007/s40291-026-00886-x","url":null,"abstract":"<p><strong>Background: </strong>Circulating C-terminal agrin fragment (CAF22) is a biomarker of neuromuscular junction degradation and sarcopenia. However, its relationship with objective measures of physical performance has not been systematically evaluated. This systematic review and meta-analysis examined associations of circulating CAF22 concentrations with gait speed and Short Physical Performance Battery (SPPB) scores in aging and chronic disease populations.</p><p><strong>Methods: </strong>PubMed, Scopus, Web of Science, and Google Scholar were searched to identify studies reporting associations between circulating CAF22 concentrations and gait speed and/or SPPB scores. Correlation coefficients were extracted, transformed to Fisher's z values, and pooled using random-effects meta-analysis. Risk of bias, heterogeneity, subgroup differences, and publication bias were assessed.</p><p><strong>Results: </strong>Twenty-one studies met the inclusion criteria, contributing 33 cohorts for gait speed (n = 3136) and 28 cohorts for SPPB (n = 2773). Higher circulating CAF22 concentrations were significantly associated with slower gait speed in controls (r = - 0.309, 95% CI - 0.371 to - 0.244%) and disease cohorts (r = - 0.309, 95% CI - 0.361 to - 0.254%), yielding an overall pooled correlation of r = - 0.308 (95% CI - 0.346 to - 0.269%). CAF22 concentrations were also inversely associated with SPPB scores in controls (r = - 0.335, 95% CI - 0.415 to - 0.250%) and disease cohorts (r = - 0.368, 95% CI - 0.422 to - 0.312%), with an overall pooled correlation of r = - 0.353 (95% CI - 0.397 to - 0.307%). No significant subgroup differences were detected.</p><p><strong>Conclusions: </strong>Elevated circulating CAF22 concentrations are consistently associated with poorer physical performance across healthy and chronic disease populations, supporting CAF22 as a promising biomarker of functional decline.</p>","PeriodicalId":49797,"journal":{"name":"Molecular Diagnosis & Therapy","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2026-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149418478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrative Omics of Eosinophils in Asthma and COPD: Deciphering Molecular Signatures for Targeted Therapy. 哮喘和COPD中嗜酸性粒细胞的综合组学:解读靶向治疗的分子特征。
IF 5.8 3区 医学
Molecular Diagnosis & Therapy Pub Date : 2026-11-01 Epub Date: 2026-08-22 DOI: 10.1007/s40291-026-00877-y
Jun Miyata, Keeya Sunata, Hisashi Sasaki, Shotaro Chubachi, Yoshinori Hasegawa, Yusuke Kawashima, Makoto Arita, Koichi Fukunaga
{"title":"Integrative Omics of Eosinophils in Asthma and COPD: Deciphering Molecular Signatures for Targeted Therapy.","authors":"Jun Miyata, Keeya Sunata, Hisashi Sasaki, Shotaro Chubachi, Yoshinori Hasegawa, Yusuke Kawashima, Makoto Arita, Koichi Fukunaga","doi":"10.1007/s40291-026-00877-y","DOIUrl":"10.1007/s40291-026-00877-y","url":null,"abstract":"<p><p>Eosinophils are central effector and regulatory cells in asthma and eosinophilic respiratory disease, and a clinically relevant subset in a proportion of patients with chronic obstructive pulmonary disease (COPD) and asthma-COPD overlap. While eosinophil counts are established biomarkers to guide corticosteroid and biologic therapy, they do not capture the molecular heterogeneity of eosinophil activation across these conditions. Advances in integrative omics now permit comprehensive profiling of eosinophils at the transcriptomic, proteomic, and lipidomic levels. In this narrative review we summarize eosinophil-focused single-omics and multi-omics studies in asthma and COPD, with an emphasis on severe eosinophilic asthma and eosinophilic COPD. Multi-omics analysis of blood eosinophils in severe asthma has revealed IL-5-dominated pathways that coexist with IL-4 and microbe-responsive programs. In contrast, eosinophils in asthma-COPD overlap and eosinophilic COPD exhibit prominent interferon-γ, tumor necrosis factor-α, and IL-33 signatures. Mechanistic studies further demonstrate that IL-4/IL-13 enhances eosinophil responsiveness to IL-33 and that IL-33 induces extracellular trap formation (ETosis). We discuss how these disease- and context-specific molecular programs may refine biomarker interpretation and inform the rational selection of biologics targeting IL-5/IL-5R, IL-4Rα, TSLP, and IL-33/ST2 in asthma and COPD.</p>","PeriodicalId":49797,"journal":{"name":"Molecular Diagnosis & Therapy","volume":" ","pages":"909-925"},"PeriodicalIF":5.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148800670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bridging Biomarker Testing to Biomarker-Driven Targeted Therapy: Real-World ESR1 Mutation Testing Patterns and Prevalence in ER+, HER2- Metastatic Breast Cancer. 连接生物标志物检测到生物标志物驱动的靶向治疗:真实世界ESR1突变检测模式和ER+, HER2-转移性乳腺癌的患病率。
IF 5.8 3区 医学
Molecular Diagnosis & Therapy Pub Date : 2026-11-01 Epub Date: 2026-09-08 DOI: 10.1007/s40291-026-00876-z
Chi-Yin Liao, Jincy John, Precious Anyanwu, Manali A Bhave, Francois-Clement Bidard, Tyler Marquart, Francisco Sapunar, Aarti Chawla, Lindsay A Williams
{"title":"Bridging Biomarker Testing to Biomarker-Driven Targeted Therapy: Real-World ESR1 Mutation Testing Patterns and Prevalence in ER+, HER2- Metastatic Breast Cancer.","authors":"Chi-Yin Liao, Jincy John, Precious Anyanwu, Manali A Bhave, Francois-Clement Bidard, Tyler Marquart, Francisco Sapunar, Aarti Chawla, Lindsay A Williams","doi":"10.1007/s40291-026-00876-z","DOIUrl":"10.1007/s40291-026-00876-z","url":null,"abstract":"<p><strong>Background: </strong>The estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer (MBC) treatment landscape continues to evolve with targeted therapy development. Estrogen receptor 1 (ESR1) testing is recommended at recurrence or each progression event to identify patients for effective therapies. However, there is limited information on testing and mutation patterns in the real world that can inform patient identification in the clinic.</p><p><strong>Methods: </strong>A retrospective observational study among patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative MBC who initiated first line (1L) therapy with aromatase inhibitors or selective estrogen receptor degraders ± CDK4/6 inhibitors from 1 January, 2020 to 31 March, 2025, using the Flatiron Health Research Database was conducted. ESR1 testing and mutation positivity rates at 1L to third line initiation, stratified by endocrine-resistant, 1L endocrine-sensitive, and endocrine-sensitive/de novo MBC were descriptively reported.</p><p><strong>Results: </strong>Overall testing rates varied across subgroups, with one or more ESR1 test per patient in 61.2% of patients with endocrine-resistant MBC (n = 2152), 50.5% in patients with 1L endocrine-sensitive MBC (n = 827), and 43.1% in patients with endocrine-sensitive/de novo MBC (n = 5772). Testing rates at 1L initiation were 36.2% in endocrine-resistant MBC and 19.6% in endocrine-sensitive/de novo MBC. Testing rates were approximately 32% at second line and 25% at third line across subgroups. ESR1 mutation positivity (ESR1m+) rates varied by subgroup at 1L initiation and were highest among patients with endocrine-resistant MBC (24.7%), followed by patients with 1L endocrine-sensitive MBC (6.9%) and patients with endocrine-sensitive/de novo MBC (2.1%). All groups had ESR1m+ rates around 30% at second line initiation and 40% at third line initiation. In an exploratory analysis, ~ 60% of ESR1 tests during 1L were conducted in tissue and ~ 40% in blood.</p><p><strong>Conclusions: </strong>In this population, real-world ESR1 testing rates were low. One in four patients with endocrine-resistant MBC were ESR1m+ at 1L initiation, ~ 30% were ESR1m+ at second line across subgroups, and ~ 40% were ESR1m+ at third line across subgroups. More blood-based testing at recurrence and progression is recommended in the real world to align with guideline recommendations as ESR1m detection is more sensitive in blood than in tissue.</p>","PeriodicalId":49797,"journal":{"name":"Molecular Diagnosis & Therapy","volume":" ","pages":"957-967"},"PeriodicalIF":5.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13710441/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148914014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mapping the Synaptome in Neurodegeneration: Emerging Clinical Applications of SV2A PET Imaging. 神经退行性变中的突触组映射:SV2A PET成像的新临床应用。
IF 5.8 3区 医学
Molecular Diagnosis & Therapy Pub Date : 2026-11-01 Epub Date: 2026-08-11 DOI: 10.1007/s40291-026-00871-4
Luca Filippi, Susanna Nuvoli, Angela Spanu, Barbara Palumbo
{"title":"Mapping the Synaptome in Neurodegeneration: Emerging Clinical Applications of SV2A PET Imaging.","authors":"Luca Filippi, Susanna Nuvoli, Angela Spanu, Barbara Palumbo","doi":"10.1007/s40291-026-00871-4","DOIUrl":"10.1007/s40291-026-00871-4","url":null,"abstract":"<p><p>Synaptic loss is a core pathological feature of neurodegenerative disorders and closely relates to cognitive and functional decline. Positron emission tomography (PET) targeting synaptic vesicle glycoprotein 2A (SV2A) has recently emerged as a promising tool for the indirect assessment of presynaptic alterations in the living human brain. This leading article discusses the evolving clinical landscape of SV2A PET across the neurodegenerative spectrum, emphasizing its translational trajectory and emerging applications. Current evidence spans Alzheimer's disease (AD), other dementias, movement disorders, Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS). The literature is currently dominated by PET with [<sup>11</sup>C]UCB-J, while [<sup>18</sup>F]-labeled tracers, particularly [<sup>18</sup>F]SynVesT-1, are expanding clinical feasibility through longer half-life and broader distribution potential. Across disorders, PET consistently detected SV2A reductions that frequently correlated with cognition, disease severity, and complementary biomarkers, including amyloid, tau, glucose metabolism, and dopaminergic imaging. Although the field remains limited by small cohorts, heterogeneous quantification strategies, and incomplete longitudinal validation, SV2A PET is rapidly evolving into a promising translational tool for studying synaptopathies and monitoring disease progression.</p>","PeriodicalId":49797,"journal":{"name":"Molecular Diagnosis & Therapy","volume":" ","pages":"845-863"},"PeriodicalIF":5.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13710587/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148708286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bile Cell-Free DNA as a Tumor-Proximal Source for Molecular Profiling of Biliary Tract Cancer: A Systematic Review and Meta-Analysis. 无胆管细胞DNA作为胆道癌分子谱的肿瘤近端来源:系统回顾和荟萃分析。
IF 5.8 3区 医学
Molecular Diagnosis & Therapy Pub Date : 2026-11-01 Epub Date: 2026-08-13 DOI: 10.1007/s40291-026-00870-5
Jun-Ha Jang, Gi Yeon Lee, Jung Won Chun, Sang-Jae Park, Seung-Kwon Myung, Sun-Young Kong
{"title":"Bile Cell-Free DNA as a Tumor-Proximal Source for Molecular Profiling of Biliary Tract Cancer: A Systematic Review and Meta-Analysis.","authors":"Jun-Ha Jang, Gi Yeon Lee, Jung Won Chun, Sang-Jae Park, Seung-Kwon Myung, Sun-Young Kong","doi":"10.1007/s40291-026-00870-5","DOIUrl":"10.1007/s40291-026-00870-5","url":null,"abstract":"<p><strong>Background: </strong>Molecular profiling is increasingly required for treatment selection in advanced biliary tract cancer, yet tumor tissue is often insufficient and plasma circulating tumor DNA has limited yield. Because bile directly contacts the biliary epithelium and is obtainable during routine biliary interventions, bile cell-free DNA (cfDNA) may provide a tumor-proximal molecular profiling source.</p><p><strong>Objective: </strong>We systematically reviewed and quantitatively synthesized bile cfDNA detection and profiling in biliary tract cancer.</p><p><strong>Methods: </strong>PubMed, EMBASE, and the Cochrane Library were searched from inception to 13 October, 2025 for studies that included at least ten patients with suspected or confirmed biliary tract cancer and extractable bile cfDNA outcomes. Pooled proportions were estimated using random-effects models with Freeman-Tukey double-arcsine transformation. Bile-versus-plasma detection was compared using pooled log risk ratios. Heterogeneity was quantified by I<sup>2</sup>, with a 95% prediction interval for the primary conservative estimate. Risk of bias was assessed with the Quality Assessment of Diagnostic Accuracy Studies-2 tool.</p><p><strong>Results: </strong>Eight studies including 271 patients with biliary tract cancer were included. After excluding two cohorts with 100% detection, the conservative pooled bile cfDNA molecular detection rate was 59.1% (95% confidence interval [CI] 49.0-68.7; I<sup>2</sup> = 50.4%) with a 95% prediction interval of 33.3-82.5%. Bile cfDNA showed higher molecular detection than plasma cfDNA in within-study comparisons (risk ratio 1.58, 95% CI 1.19-2.10; I<sup>2</sup> = 0%), with directionally higher allele fractions in bile. Bile-tissue concordance was 82.7% (95% CI 69.1-93.5; I<sup>2</sup> = 43.7%). Among patients with non-diagnostic biliary cytology, incremental molecular detection yield was 36.6% (95% CI 26.9-46.9; I<sup>2</sup> = 0%). Potentially actionable FGFR2 fusions, IDH1 mutations, and ERBB2 alterations were reported across five studies but were summarized descriptively because actionability definitions and reporting units varied.</p><p><strong>Conclusions: </strong>Bile cfDNA showed higher molecular detection than plasma cfDNA and supported molecular profiling when tumor tissue was insufficient, but detection and endpoint heterogeneity limit its use as a stand-alone diagnostic test. Its role is best defined as opportunistic molecular profiling during indicated biliary procedures, pending prospective multicenter validation with standardized protocols.</p><p><strong>Protocol registration: </strong>PROSPERO CRD420251250742 (registered prospectively prior to study conduct).</p>","PeriodicalId":49797,"journal":{"name":"Molecular Diagnosis & Therapy","volume":" ","pages":"875-888"},"PeriodicalIF":5.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148765395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rapid Ex Vivo Visualization of Laryngeal Tumors Using a Sprayable pH-Activatable Fluorophore. 使用可喷雾的ph活化荧光团快速观察喉部肿瘤。
IF 5.8 3区 医学
Molecular Diagnosis & Therapy Pub Date : 2026-11-01 Epub Date: 2026-09-11 DOI: 10.1007/s40291-026-00878-x
Daan G J Linders, Sebastiaan W R Dalmeijer, Bo E Zweedijk, Hamed Abbasi, Danielle Boldewijn, Sjors A Koppes, Bernd Kremer, Jacobus Burggraaf, Denise E Hilling, Joost R van der Vorst, Jinhui Ser, Satoshi Kashiwagi, Maged Henary, Jeroen C Jansen, Alexander L Vahrmeijer, Hak Soo Choi, Stijn Keereweer
{"title":"Rapid Ex Vivo Visualization of Laryngeal Tumors Using a Sprayable pH-Activatable Fluorophore.","authors":"Daan G J Linders, Sebastiaan W R Dalmeijer, Bo E Zweedijk, Hamed Abbasi, Danielle Boldewijn, Sjors A Koppes, Bernd Kremer, Jacobus Burggraaf, Denise E Hilling, Joost R van der Vorst, Jinhui Ser, Satoshi Kashiwagi, Maged Henary, Jeroen C Jansen, Alexander L Vahrmeijer, Hak Soo Choi, Stijn Keereweer","doi":"10.1007/s40291-026-00878-x","DOIUrl":"10.1007/s40291-026-00878-x","url":null,"abstract":"<p><strong>Introduction: </strong>Achieving clear resection margins (> 5 mm) is critical during laryngeal and hypopharyngeal tumor resection, as positive margins are associated with reduced disease-specific survival. Near-infrared (NIR) fluorescence imaging has emerged as a valuable tool for intraoperative margin assessment by enabling real-time visualization of residual tumor tissue. However, current fluorescent contrast agents rely on intravenous administration, often requiring dosing hours to days before surgery. Also, targeting tumor-specific biomarkers with heterogeneous expression limits applicability. To address these limitations, we evaluated the feasibility of a topically applied pH-activatable fluorophore (PH10), which selectively fluoresces under acidic conditions. This ex vivo proof-of-concept study investigates whether topical PH10 can visualize laryngeal and hypopharyngeal tumors.</p><p><strong>Methods: </strong>Freshly resected laryngeal and hypopharyngeal squamous cell carcinoma (SCC) specimens were obtained from ten patients and topically sprayed with PH10 immediately after surgery. Following a 2-min incubation period, NIR fluorescence images were acquired before and after three sequential saline washes. Fluorescence intensity was quantified as the tumor-to-background ratio (TBR); tumor localization was confirmed on histopathology.</p><p><strong>Results: </strong>Laryngeal tumors demonstrated tumor-specific fluorescence upon PH10 application, with significantly higher signal intensity in tumor tissue compared to adjacent normal mucosa (P < 0.05). The median TBR after the first wash was 2.3 (interquartile range 1.7-3.0), exceeding the clinically relevant threshold of 1.5 in seven of seven laryngeal SCC cases; however, this threshold was not reached in either of the two hypopharyngeal carcinoma cases included.</p><p><strong>Conclusions: </strong>This proof-of-concept study suggests that PH10, a sprayable pH-activatable fluorophore, can enable rapid and high-contrast visualization of laryngeal tumors, although this was not observed in the small number of hypopharyngeal cases evaluated. Given its topical application and rapid activation, PH10 may hold promise for intraoperative margin assessment, yet these preliminary findings, based on a small and heterogeneous sample, require validation in larger cohorts, including direct correlation with deep resection margins, before clinical utility can be established.</p>","PeriodicalId":49797,"journal":{"name":"Molecular Diagnosis & Therapy","volume":" ","pages":"969-978"},"PeriodicalIF":5.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13710600/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148944703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost-Effectiveness of a Host-Response Point-of-Care Assay for Early Sepsis Diagnosis in UK Emergency Departments. 英国急诊科早期败血症诊断的宿主反应点检测的成本效益
IF 5.8 3区 医学
Molecular Diagnosis & Therapy Pub Date : 2026-11-01 Epub Date: 2026-08-11 DOI: 10.1007/s40291-026-00860-7
Erika P Plata-Menchaca, Enrique Hernández-Jiménez, Queralt Caus-Capdevila, Judit Cubedo, Eduard Guerrero, Ignasi Azagra, Joan Vieyra, Francisco Eduardo Dardón-Fierro, Jia Louise, Kate Zhang, Cheryl McDade, Christopher Knight, David Price, Bob Jarman, Ricard Ferrer
{"title":"Cost-Effectiveness of a Host-Response Point-of-Care Assay for Early Sepsis Diagnosis in UK Emergency Departments.","authors":"Erika P Plata-Menchaca, Enrique Hernández-Jiménez, Queralt Caus-Capdevila, Judit Cubedo, Eduard Guerrero, Ignasi Azagra, Joan Vieyra, Francisco Eduardo Dardón-Fierro, Jia Louise, Kate Zhang, Cheryl McDade, Christopher Knight, David Price, Bob Jarman, Ricard Ferrer","doi":"10.1007/s40291-026-00860-7","DOIUrl":"10.1007/s40291-026-00860-7","url":null,"abstract":"<p><strong>Background: </strong>Early recognition of sepsis in emergency departments (EDs) improves outcomes and reduces healthcare resource use. However, current clinical practice (CCP), largely based on the National Early Warning Score 2 (NEWS2) and clinical judgement, has limited diagnostic sensitivity at presentation. Consequently, some patients with early sepsis are not promptly identified, resulting in delayed treatment, disease progression, and increased use of high-cost care. Rapid point-of-care host-response diagnostics may complement clinical assessment by identifying patients at risk who do not initially meet conventional clinical thresholds.</p><p><strong>Objective: </strong>To estimate the cost-effectiveness of adding a rapid LPS-induced TNF-α release point-of-care assay (TARA) to current clinical practice, compared with procalcitonin (PCT) plus CCP and CCP alone, from the UK National Health Service (NHS) and Personal Social Services perspective, in line with NICE reference case methods.</p><p><strong>Methods: </strong>A decision-analytic model simulated diagnostic classification, timing of sepsis recognition (early, delayed, late), initiation of antibiotic treatment, hospital admission (general ward or intensive care unit [ICU]), discharge, and readmission among adults presenting to UK EDs with suspected sepsis without shock. Model inputs included diagnostic accuracy, clinical outcomes, health-related quality of life, and costs derived from published literature and UK-relevant sources. The base-case time horizon was lifetime, to fully capture the QALY consequences of prevented deaths and long-term sequelae (ESRD, amputation); a 6-month scenario analysis was also conducted. Deterministic and probabilistic sensitivity analyses assessed parameter uncertainty.</p><p><strong>Results: </strong>In the deterministic base-case analysis, TARA plus CCP was associated with lower total costs and higher quality-adjusted life-years (QALYs) compared with both comparator strategies. Cost savings were approximately £370 per patient versus PCT plus CCP and £1,822 per patient versus CCP alone, with incremental QALY gains of 0.0834 and 0.0836, respectively. In the probabilistic analysis, mean cost savings were £391 versus PCT plus CCP and £1,835 versus CCP alone. Benefits were driven primarily by reductions in false-negative diagnoses, leading to earlier treatment, lower ICU use, and reduced downstream hospital costs.</p><p><strong>Conclusions: </strong>Integrating a rapid host-response point-of-care assay into ED sepsis pathways in the UK was associated with lower total costs (savings of approximately £370 per patient versus PCT plus CCP and £1,822 per patient versus CCP alone) and marginally higher quality-adjusted life-years (QALY gains of 0.0834 and 0.0836, respectively), driven by reductions in missed diagnoses and downstream use of high-cost care.</p>","PeriodicalId":49797,"journal":{"name":"Molecular Diagnosis & Therapy","volume":" ","pages":"979-992"},"PeriodicalIF":5.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13710613/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148708377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Orca-T: First Approval. Orca-T:第一次批准。
IF 5.8 3区 医学
Molecular Diagnosis & Therapy Pub Date : 2026-11-01 Epub Date: 2026-09-17 DOI: 10.1007/s40291-026-00882-1
Hannah A Blair
{"title":"Orca-T: First Approval.","authors":"Hannah A Blair","doi":"10.1007/s40291-026-00882-1","DOIUrl":"10.1007/s40291-026-00882-1","url":null,"abstract":"<p><p>Allogeneic regulatory T cell immunotherapy with haematopoietic stem and progenitor cells (HSPC) and T cells-vldq, hereafter referred to as Orca-T (TREGZI<sup>™</sup>), has been developed by Orca Bio under license from Stanford University for the prevention of chronic graft-versus-host disease (cGVHD). On 30 June 2026, Orca-T received its first approval in the USA for use in matched donor haematopoietic stem cell transplantation (HSCT) with myeloablative preparative regimen, for haematopoietic and immunologic reconstitution and to improve cGVHD-free survival, in the treatment of adults with haematological malignancies. This article summarizes the milestones in the development of Orca-T leading to this first approval for the prevention of cGVHD.</p>","PeriodicalId":49797,"journal":{"name":"Molecular Diagnosis & Therapy","volume":" ","pages":"1003-1008"},"PeriodicalIF":5.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148992255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Non-Invasive Prenatal Testing in Donor-Oocyte Pregnancies: Biological Determinants, Algorithmic Limitations and Clinical Implications. 供体-卵母细胞妊娠的无创产前检测:生物学决定因素、算法限制和临床意义。
IF 5.8 3区 医学
Molecular Diagnosis & Therapy Pub Date : 2026-11-01 Epub Date: 2026-08-08 DOI: 10.1007/s40291-026-00866-1
Michele Miscia, Irene Pesaresi, Benedetta Dini, Danila Morano, Paolo Ivo Cavoretto, Antonio Farina
{"title":"Non-Invasive Prenatal Testing in Donor-Oocyte Pregnancies: Biological Determinants, Algorithmic Limitations and Clinical Implications.","authors":"Michele Miscia, Irene Pesaresi, Benedetta Dini, Danila Morano, Paolo Ivo Cavoretto, Antonio Farina","doi":"10.1007/s40291-026-00866-1","DOIUrl":"10.1007/s40291-026-00866-1","url":null,"abstract":"<p><p>Non-invasive prenatal testing (NIPT) based on circulating cell-free DNA (cfDNA) has transformed prenatal screening for common aneuploidies, but its interpretation is less straightforward in pregnancies conceived with donor oocytes. In this setting, fetal chromosomal risk is largely donor-driven, whereas cfDNA interpretability is shaped mainly by the recipient and the placenta. Donor-oocyte pregnancies are enriched for advanced maternal age, obesity, hypertensive and immunologic complications, low-molecular-weight heparin exposure, multiple gestation, vanishing twin, and placental dysfunction - all factors that can destabilize the cfDNA signal. Fetal fraction should therefore be read not only as a technical quality metric but also as a biological marker of placental performance. Analytical platform behavior also matters; counting-based and single-nucleotide polymorphism-based approaches may behave differently in biologically complex samples, particularly for sex chromosome findings and in the setting of maternal confounding. In donor-oocyte pregnancies, a no-call result may be clinically informative rather than neutral. Pre-test counseling, explicit communication with the laboratory, availability of fetal-fraction reporting, and integration with first-trimester ultrasound are essential. Donor-oocyte pregnancy should be regarded as a biologically distinct model for cfDNA screening, one that exposes the limits of generic NIPT algorithms and argues for more tailored interpretation.</p>","PeriodicalId":49797,"journal":{"name":"Molecular Diagnosis & Therapy","volume":" ","pages":"865-874"},"PeriodicalIF":5.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13710627/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148698242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unfolded Protein Response Pathways in Cancer: Mechanisms, Tumor Biology and Therapeutic Opportunities. 未折叠蛋白在癌症中的反应途径:机制、肿瘤生物学和治疗机会。
IF 5.8 3区 医学
Molecular Diagnosis & Therapy Pub Date : 2026-11-01 Epub Date: 2026-08-07 DOI: 10.1007/s40291-026-00869-y
Mercilena Benjamin, Surender Kumar Sharawat, Anita Chopra
{"title":"Unfolded Protein Response Pathways in Cancer: Mechanisms, Tumor Biology and Therapeutic Opportunities.","authors":"Mercilena Benjamin, Surender Kumar Sharawat, Anita Chopra","doi":"10.1007/s40291-026-00869-y","DOIUrl":"10.1007/s40291-026-00869-y","url":null,"abstract":"<p><p>Endoplasmic reticulum (ER) is a multifunctional organelle essential for maintaining proteostasis, lipid and carbohydrate metabolism, and calcium homoestasis. Rapidly dividing cancer cells driven by oncogenes, elevated translational output, increased metabolic demands, and a hostile tissue microenvironment overwhelm the protein-folding machinery of ER, leading to massive accumulation of unfolded proteins within the ER's lumen leading to chronic ER stress. This activates the unfolded protein response (UPR), a conserved signaling network mediated by three principal sensors: protein kinase R-like endoplasmic reticulum kinase (PERK), inositol-requiring enzyme 1-alpha (IRE1α), and activating transcription factor 6 (ATF6), which functions to restore proteostasis or induce apoptosis under unresolved ER stress. Accumulating evidence indicates that malignant cells hijack the pro-adaptive function of the UPR pathway not only to thrive but also to promote cancer progression by invasion and metastasis. UPR activation modulates transcriptional and translational programs that contribute to angiogenesis, invasion, metastasis, immune escape, and chemoresistance. In this review, we dissect how cells balance this tightrope between adaptation and cell death in the context of cancer. We also explore how UPR signaling drives angiogenesis, metastasis, immune-evasion, and chemoresistance before finally discussing its therapeutic potential.</p>","PeriodicalId":49797,"journal":{"name":"Molecular Diagnosis & Therapy","volume":" ","pages":"927-955"},"PeriodicalIF":5.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148686515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书